Ashraf Al-Ouf, head of pharmaceutical commercial operations, Apac at Bayer spoke to Teena Thacker about the company’s moves towards innovation and clinical research for the region. He said the company is poised to address healthcare needs and offer new therapeutic options to patients across the Apac. Edited excerpts: There are 34 clinical trials ongoing in…
San Sebastian (Spain): Pharmaceutical major Bayer has filed for approval to market its patented drug finerenone in India for treating certain heart failure patients, a potential boost in a country increasingly grappling with early onset of heart disease. Finerenone, branded as Kerendia, received USFDA approval in July 2025 for treatment of heart failure with a…
Shilpa Medicare gets initial authorization from EMA for Rivaroxaban Orodispersible Films We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Bayer’s much-anticipated stem cell therapy for Parkinson’s disease is gathering momentum, with dosing in phase 3 trials now underway. The first patient has already been treated with bemdaneprocel, a one-shot treatment designed to replace the dopamine-producing neurons that degenerate in Parkinson’s, which is being developed by Bayer’s BlueRock Therapeutics subsidiary. Meanwhile, Bayer is also making…
Bayer new drug application for gadoquatrane accepted for review in China We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Bayer Elinzanetant recommended for nod in EU for moderate to severe vasomotor symptoms We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Tata Elxsi inaugrates Bayer Development Centre in Radiology at Pune We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Bayer Gadoquatrane new drug application accepted for review by USFDA We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Bayer, Kumquat Biosciences ink pact to develop, commercialize KRAS G12D inhibitor We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link